PATENT CLAIM ANALYSIS

Application Number: 16196726
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "401000"]

Abstract:
The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.

Claim (Index 5):
The method of  claim 1 , wherein the one or more GABAergic agents or pharmaceutically acceptable salts thereof is selected from the group consisting of gabapentin, bamaluzole, gaboxadol, ibotenic acid, muscimol, progabide, SL 75102, thiomuscimol, tolgabide, a benzodiazepine, chlormezanone, clomethiazole, etomidate, loreclezole, a piperidinedione, propanidid, a pyrazolopyridine, a quinazolinone, ROD-188, skullcap, stiripentol, thymol, valerenic acid, bicuculline, gabazine, pitrazepin, a5IA, bilobalide, cicutoxin, cyclothiazide, DMCM, flumazenil, flurothyl, furosemide, L-655,708, oenanthotoxin, pentylene tetrazol, picrotoxin, PWZ-029, R015-4513, sarmazenil, suritozole, thujone, thiocolchicoside, 1,4-butanediol, baclofen, beta-phenyl-gamma aminobutyric acid, phaclofen, saclofen, progabide, tolgabide, biolbalide TPMPA, GABA reuptake inhibitors, gabapentin, L-theanine, picamilon and pregabalin.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 98.0
- Lexical Diversity: 1.19231
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14231096', '13262704', '14027033', '15490011', '15498991']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7657376137026016
- 35 USC 102 Novelty (BERT): 0.5756730177677933
- Combined Prediction Score: 0.7467311541091208
- Mean Citation Score: 239.13687400000003
- Max Citation Score: 512.20874
- Similarity Product: 369.16674260099177

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test